Xenograft experiments demonstrated that Tim-3+ AML cells were able to initiate human AML in NSG mice and anti-Tim-3 mAb treatment dramatically depleted LSCs and leukemic burden in primary and secondary NSG recipients [84]. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.